After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Ambrx Announces Sale to Johnson & Johnson.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Ambrx Biopharma Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Ambrx Biopharma Inc. is $1.77B. A total of 2.31 million shares were traded on the day, compared to an average of 1.91M shares.
In the most recent transaction, O’Connor Daniel J. sold 50,012 shares of AMAM for 9.82 per share on Oct 27. After the transaction, the President and CEO now owns 342,845 company shares. In a previous transaction on Oct 27, Nelson Sonja sold 12,778 shares at 9.82 per share. AMAM shares that Chief Financial Officer owns now total 130,079.
Among the insiders who bought shares, Cormorant Asset Management, LP acquired of 1,307,311 shares on Oct 23 at a per-share price of $6.99. This resulted in the 10% Owner holding 11,231,000 shares of AMAM after the transaction. In another insider transaction, Cormorant Asset Management, LP bought 751,233 shares at $9.24 per share on Sep 18. Company shares held by the 10% Owner now total 69,465,823.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, AMAM has a high of $28.15 and a low of $5.56.
As of this writing, AMAM has an earnings estimate of -$0.39 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.34 per share and a lower estimate of -$0.45. The company reported an EPS of -$0.35 in the last quarter, which was -288.90% lower than expectations of -$0.09.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. AMAM’s latest balance sheet shows that the firm has $170.06M in Cash & Short Term Investments as of fiscal 2021. There were $13.13M in debt and $24.58M in liabilities at the time. Its Book Value Per Share was $4.05, while its Total Shareholder’s Equity was $189.97M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AMAM is Buy with a score of 3.78.
